Table 1 Participant descriptive, medical and oncological variables (n = 13).
Mean (SD) | Min–Max | |
|---|---|---|
Age (years) | 48.69 (7.20) | 40–59 |
Weight (kg) | 74.78 (17.90) | 51–119.50 |
Height (m) | 1.63 (0.06) | 1.57–1.79 |
BMI (kg/m2) | 27.12 (5.76) | 19.84–36.72 |
Time since diagnosis (in years) | 2.67 (0.81) | 1.10–3.00 |
Time since metastasis diagnosis (in months) | 26.25 (36.02) | 0.50–180.00 |
Outcome | Value (%) | |
|---|---|---|
Surgery intervention | Mastectomy | 7 (53.85%) |
Breast-conserving | 2 (15.38%) | |
None | 4 (30.77%) | |
Systemic treatment | Chemotherapy | 13 (100.00%) |
Hormone therapy | 11 (84.62%) | |
Monoclonal antibody | 6 (46.15%) | |
Radiotherapy | 4 (30.77%) | |
Metastatic disease site | Visceral (liver, lung or CNS) | 13 (100.00%) |
Non-visceral | 10 (76.92%) | |
Visceral and Non-visceral | 10 (76.92%) | |
Bone metastases | Subjects with bone metastases | 10 (76.92%) |
Spine | 8 (61.48%) | |
Femur | 5 (38.46%) | |
Pelvis | 5 (38.46%) | |
Thorax | 5 (15.38%) | |
Humerus | 2 (38.46%) | |
Type of bone metastases | Mixed | 5 (38.46%) |
Osteoblast | 4 (30.77%) | |
Osteolytic | 1 (7.69%) | |
Current treatment | Chemotherapy | 4 (30.77%) |
Hormone therapy | 8 (61.48%) | |
Monoclonal antibody | 4 (30.77%) | |
Radiotherapy | 4 (30.77%) |
